Treatment of acute myeloid leukemia in older patients

Expert Review of Anticancer Therapy

Volumn 7, Issue 3, 2007, Pages 285-295

  Roboz, Gail J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acute myeloid leukemia; Cytogenetics; Elderly; Low dose cytabine; Novel agents

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CEP 701; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; INTERFERON; LONAFARNIB; MIDOSTAURIN; MITOXANTRONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RETINOIC ACID; SUNITINIB; TIOGUANINE; TIPIFARNIB; UNINDEXED DRUG; VALPROIC ACID; VALSPODAR; VORINOSTAT; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BRAIN TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOGENETICS; DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG SYNTHESIS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA REMISSION; LEUKOCYTOSIS; LIVER DISEASE; LOW DRUG DOSE; MONOTHERAPY; OVERALL SURVIVAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SIGNAL TRANSDUCTION;

ACUTE DISEASE; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYTARABINE; DISEASE MANAGEMENT; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; FARNESYLTRANSTRANSFERASE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

EID: 33947677691     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.3.285     Document Type: Review

References (81)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin. 56(2), 106-130 (2006).
2. Burnett AK, Mohite U. Treatment of older patients with acute myeloid leukemia - new agents. Semin. Hematol 43(2), 96-106 (2006).
3. Mrozek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. In: The American Society of Hematology Education Program Book. American Society of Hematology, DC, USA 169-177 (2006).
4. Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89(9), 3323-3329 (1997).
5. Menzin J. Effects of initial treatment on survival among elderly AML patients: findings from the SEER-Medicare database. Blood 108(11), A558 (2006).
6. Larson R. Fifty years of clinical research by the Leukemia Committee of the Cancer and Leukemia Group B. Clin. Cancer Res. 12(Suppl. 11), 3556-3563 (2006).
7. Lowenberg B, Zittoun R, Kerkhofs H et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized Phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J. Clin. Oncol, 7(9), 1268-1274 (1989).
8. Tilly H, Castaigne S, Bordessoule D et al. Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients. Cancer 55(8), 1633-1636 (1985).
9. Roberts JD, Ershler WB, Tindle BH, Stewart JA. Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia. Cancer 56(5), 1001-1005 (1985).
10. Degos L, Castaigne S, Tilly H, Sigaux F, Daniel MT. Treatment of leukemia with low-dose ara-C: a study of 160 cases. Semin. Oncol 12(2 Suppl. 3), 196-199 (1985).
11. Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J. Clin. Oncol. 4(12), 1857-1864 (1986).
12. Burnett A. Low-dose ara-C with or without retinoid in older patients not considered fit for intensive chemotherapy. Blood 104, A249 (2004).
13. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch. Intern. Med. 162(14), 1597-1603 (2002).
14. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341(27), 2061-2067 (1999).
15. Esrey EH. General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin. Hematol, 43(2), 89-95 (2006).
16. Grimwade D, Walker H, Harrison G et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98(5), 1312-1320 (2001).
17. Estey E, Thall P, Beran M et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 90(8), 2969-2977 (1997).
18. Kantarjian H, O'Brien S, Cortes J et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106(5), 1090-1098 (2006).
19. Baudard M, Beauchamp-Nicoud A, Delmer A et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia 13(10), 1481-1490 (1999).
20. Johnson PR, Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia. Leuk. Lymphoma 16(1-2), 51-56 (1994).
21. Frohling S, Schlenk RF, Kayser S et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 108(10), 3280-3288 (2006).
22. Gupta V, Chun K, Yi QL et al. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 103(10), 2082-2090 (2005).
23. Marcucci G, Mrozek K, Ruppert AS et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J. Clin. Oncol. 23(24), 5705-5717 (2005).
24. Schoch C, Kern W, Schnittger S et al. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenctic subgroups. Haematologica 89(9), 1082-1090 (2004).
25. Appelbaum FR, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood 107(9), 3481-3485 (2006).
26. Giles FJ, Borthakur G, Ravandi F et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br. J Haematol. (2007) (Epub ahead of print).
27. Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8), 2912-2919 (2005).
28. List AF, Kopecky KJ, Willman CL et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98(12), 3212-3220 (2001).
29. van der Holt B, Lowenberg B, Burnett AK et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106(8), 2646-2654 (2005).
30. Baer MR, George SL, Dodge RK et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720. Blood 100(4), 1224-1232 (2002).
31. Cripe LD, Li X, Litzow M et al. A randomized, placebo-controlled, double blind trial of the MDR modulator, zosuquidar, during conventional induction and post-remission therapy for pts > 60 years of age with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): ECOG 3999. Blood 108, A129 (2006).
32. Larson RA, Boogaerts M, Esrey E et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 16(9), 1627-1636 (2002).
33. Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin. Oncol. 19(13), 3244-3254 (2001).
34. Roboz GJ, Knovich MA, Bayer RL et al. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk. Lymphoma 43(10), 1951-1955 (2002).
35. Estey EH, Thall PF, Giles FJ et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 99(12), 4343-4349(2002).
36. Amadori S, Suciu S, Stasi R et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a Phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia 19(10), 1768-1773(2005).
37. Kell WJ, Burnett AK, Chopra R et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102(13), 4277-4283 (2003).
38. Roboz GJ, Ritchie EK, Schuster MW er al. Gemtuzumab ozogamicin is an acceptable alternative to anthracyclines in combination with standard dose infusional cytarabine as induction therapy for elderly patients with acute myeloid leukemia (AML). Blood 106, A221 (2005).
39. Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 102(12), 3880-3889 (2003).
40. Lancet JE, Gojo I, Gotlib J et al. A Phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 109(4), 1387-1394 (2007).
41. Small D. FLT3 mutations: biology and treatment. In: The American Society of Hematology Education Program Book. American Society of Hematology, DC, USA 178-184 (2006).
42. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 14(4), 675-683 (2000).
43. Smith BD, Levis M, Beran M et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute mycloid leukemia. Blood 103(10), 3669-3676 (2004).
44. Stone RM, DeAngelo DJ, Klimek V et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 (1), 54-60 (2005).
45. Fiedler W, Serve H, Dohner H et al. A Phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (3), 986-993 (2005).
46. Knapper S, Mills KI, Gilkes AF et al. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 108(10), 3494-3503 (2006).
47. Knapper S, Burnett AK, Littlewood T et al. A Phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108(10), 3262-3270 (2006).
48. Giles F, Thomas D, Garcia-Manero G et al. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin. Cancer Res. 10(9), 2908-2917 (2004).
49. Giles F, Verstovsek S, Faderl S et al. A Phase II study of cloretazine (VNP40101M), a novel sulfony1hydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk. Res. 30(12), 1591-1595 (2006).
50. Vey N, Giles F. Cloretazine for the treatment of acute myeloid leukemia. Exp. Rev. Anticancer Ther. 6(3), 321-328 (2006).
51. Rizzieri DA, Tse W, Khan KD et al. A Phase I study of Cloretazine® and temozolomide in patients with hematologic malignancies. Blood 108, A557 (2006).
52. Giles F, Rizzieri D, Karp J et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin. Oncol. 25(1), 25-31 (2007).
53. Kantarjian H, Gandhi V, Cortes J et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102(7), 2379-2386 (2003).
54. Burnett AK, Baccarani M, Johnson P et al. A Phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable. Blood A130 (2006).
55. Faderl S, Verstovsek S, Cortes J et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) inpatients 50 years of age or older. Blood 108(1), 45-51 (2006).
56. Faded S, Ravandi F, Ferrajoli A et al. Clofarabine and clofarabine plus low-dose cytarabine (ara-C) as induction therapy fbr patients (pts) ≥ 60 years with newly diagnosed acute myeloid leukemia (AML). Blood 106, A786 (2005).
57. Vey N, Bosly A, Guerci A et at Arsenic trioxide in patients with myclodysplastic syndromes: a Phase II multicenter study. J Clin. Oncol. 24(16), 2465-2471 (2006).
58. Schiller GJ, Slack J, Hainsworth JD et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J. Clin. Oncol. 24(16), 2456-2464 (2006).
59. Parmar S, Rundhaugen LM, Boehlke L et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk. Res. 28(9), 909-919 (2004).
60. Douer D, Watkins K, Louie R et al. Treatment of non-APL acute myelogenous leukemia with intravenous arsenic trioxide plus ascorbic acid. Blood 108, A554 (2006).
61. Roboz GJ, Ritchie EK, Allen-Bard S et al. Arsenic trioxide (ATO) is safe and effective in combination with low-dose Ara-C (LDAC) for the treatment of IPSS-2 myelodysplastic syndrome (MDS) and poor-prognosis acute myeloid leukemia (AML) in elderly patients. Blood 106, A528 (2005).
62. de Lima M, Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin. Hematol. 43(2), 107-117 (2006).
63. Wong R, Giralt SA, Martin T et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 102(8), 3052-3059 (2003).
64. Shimoni A, Kroger N, Zabelina T et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 19(1), 7-12 (2005).
65. Hegenbart U, Niederwieser D, Sandmaier BM et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J CLin. Oncol. 24(3), 444-453 (2006).
66. Kroger N, Shimoni A, Zabetina. T et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant. 37(4), 339-344 (2006).
67. van Besien K, Ariz A, Smith S et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin. Oncol. 23(24), 5728-5738 (2005).
68. Estey E, de Lima M, Tibes R et al. Prospective feasibility analysis of reduced intensity conditioning regimens (RIC) for hematopoetic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109(4), 1395-1400 (2007)
69. Platzbecker U, Thiede C, Fussel M et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 20(4), 707-714 (2006).
70. Estey EH, Garcia-Manero G, Giles F, Kantarjian HM. Effect of failure to respond to targeted therapy on response ta cytotoxic therapy in pts age ≥ 60 with newly-diagnosed AML. Blood A556 (2006).
71. Estey EH, Bedikian SH, Witter DC, Pierce SA, Giles FJ. The predictive value of a "positive" ASH abstract in AML therapeutics. Blood A555 (2006).
72. Estey E. Clinical trials in AML of the elderly: should we change our methodology? Leukemia 18(11), 1772-1774 (2004).
73. Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N. Engl. J. Med. 331(14), 896-903 (1994).
74. Stone R. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N. Engl J. Med. 332, 1671-1677 (1995).
75. Rowe JM, Andersen JW, Mazza JJ et al. A randomized placebo-controlled Phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86(2), 457-462 (1995).
76. Godwin JE, Kopecky KJ, Head DR et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood 91 (10), 3607-3615 (1998).
77. Lowenberg B, Suciu S, Archimbaud E et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group. J Clin. Oncol. 16(3), 872-881 (1998).
78. Goldstone AH, Burnett AK, Wheatley K et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results ofthe United Kingdom Medical Research Council AML11 trial. Blood 98(5), 1302-1311 (2001).
79. Anderson JE, Kopecky KJ, Willman CL et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 100(12), 3869-3876 (2002).
80. Buchner T, Hiddemann W, Berdel WE et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J. Clin. Oncol. 21(24), 4496-4504 (2003).
81. Rowe JM, Neuberg D, Friedenberg W et al. A Phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 103(2), 479-485 (2004).